New Delhi: Remdesivir will be available to patients in India this month. Mylan NV announced on Monday that the Drug Controller General of India (DCGI) has approved it for restricted emergency use in India as part of the regulator’s accelerated approval process to address urgent, unmet needs amid the evolving COVID-19 pandemic, reported timesnownews.com
The drug will be launched under the brand name DESREMTM in India. A 100mg vial will cost Rs 4,800. This is more than 80 percent less than the price at which the branded version of this product will be available to governments in the developed world, the report said.
As per a company release, the drug is approved for the treatment of suspected or laboratory-confirmed incidences of novel coronavirus infection in adults and children hospitalised with severe presentations of the disease, the company said in a release.
Mylan will manufacture Remdesivir in India at its world-class injectables facilities.
